Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by AdvisorNet Financial Inc

AdvisorNet Financial Inc lessened its holdings in Exact Sciences Co. (NASDAQ:EXASGet Rating) by 82.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,593 shares of the medical research company’s stock after selling 11,968 shares during the quarter. AdvisorNet Financial Inc’s holdings in Exact Sciences were worth $102,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC raised its stake in shares of Exact Sciences by 6.1% in the first quarter. ARK Investment Management LLC now owns 14,323,962 shares of the medical research company’s stock worth $1,001,531,000 after purchasing an additional 827,948 shares during the last quarter. Capital World Investors raised its stake in shares of Exact Sciences by 17.2% in the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after purchasing an additional 804,159 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Exact Sciences by 149.4% in the first quarter. Farallon Capital Management LLC now owns 802,898 shares of the medical research company’s stock worth $56,139,000 after purchasing an additional 481,000 shares during the last quarter. Spyglass Capital Management LLC raised its stake in shares of Exact Sciences by 18.3% in the fourth quarter. Spyglass Capital Management LLC now owns 2,669,716 shares of the medical research company’s stock worth $207,784,000 after purchasing an additional 413,713 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Exact Sciences by 1.4% in the first quarter. Vanguard Group Inc. now owns 15,641,994 shares of the medical research company’s stock worth $1,093,688,000 after purchasing an additional 210,260 shares during the last quarter. Institutional investors and hedge funds own 90.95% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the transaction, the director now owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the transaction, the director now owns 60,318 shares of the company’s stock, valued at $2,722,754.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Katherine S. Zanotti sold 1,086 shares of the company’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the transaction, the director now directly owns 60,318 shares in the company, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,701 shares of company stock valued at $251,872. Insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

EXAS has been the subject of several research analyst reports. Evercore ISI raised their price objective on Exact Sciences to $65.00 in a research note on Tuesday, August 9th. Cowen reduced their price target on Exact Sciences from $83.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, August 3rd. Credit Suisse Group initiated coverage on Exact Sciences in a research report on Wednesday, August 24th. They set an “outperform” rating and a $55.00 price target for the company. Benchmark reduced their price target on Exact Sciences to $54.00 in a research report on Tuesday, August 9th. Finally, BTIG Research reduced their price target on Exact Sciences from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $69.14.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS opened at $36.30 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.48 and a quick ratio of 2.23. The business’s 50 day moving average price is $41.65 and its 200-day moving average price is $50.65. The firm has a market capitalization of $6.42 billion, a PE ratio of -8.58 and a beta of 1.37. Exact Sciences Co. has a 1 year low of $34.16 and a 1 year high of $106.27.

Exact Sciences Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Stories

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.